Merck� (NYSE: MRK ) , one of the biggest drugmakers on the planet, may not be among the most exciting or innovative health care companies, but it is often favored by long-term investors. In this video, health care analyst Max Macaluso dives into three compelling reasons why investors should think about buying Merck.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. For more detailed information, make sure you take a look at our�brand new premium research report�today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by�clicking here.
No comments:
Post a Comment